414 related articles for article (PubMed ID: 18788407)
1. [Dyslipidemia as a therapeutic target for prevention of cardiovascular events and end-stage renal disease].
Watanabe T
Nihon Rinsho; 2008 Sep; 66(9):1761-9. PubMed ID: 18788407
[TBL] [Abstract][Full Text] [Related]
2. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.
Kanbay M; Turgut F; Covic A; Goldsmith D
J Nephrol; 2009; 22(5):598-609. PubMed ID: 19809992
[TBL] [Abstract][Full Text] [Related]
3. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
Marrs JC; Saseen JJ
Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
[TBL] [Abstract][Full Text] [Related]
4. Management of dyslipidemias in patients with diabetes and chronic kidney disease.
Molitch ME
Clin J Am Soc Nephrol; 2006 Sep; 1(5):1090-9. PubMed ID: 17699330
[TBL] [Abstract][Full Text] [Related]
5. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
Ahmed MH; Khalil AA
Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168
[TBL] [Abstract][Full Text] [Related]
6. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
7. [Chronic kidney disease and statins].
Matovinović MS
Lijec Vjesn; 2006; 128(11-12):345-50. PubMed ID: 17212196
[TBL] [Abstract][Full Text] [Related]
8. The dyslipidemia of chronic renal disease: effects of statin therapy.
Ozsoy RC; van Leuven SI; Kastelein JJ; Arisz L; Koopman MG
Curr Opin Lipidol; 2006 Dec; 17(6):659-66. PubMed ID: 17095911
[TBL] [Abstract][Full Text] [Related]
9. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy.
Athyros VG; Mitsiou EK; Tziomalos K; Karagiannis A; Mikhailidis DP
Expert Opin Pharmacother; 2010 Apr; 11(5):723-30. PubMed ID: 20210681
[TBL] [Abstract][Full Text] [Related]
10. Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment?
Scarpioni R; Ricardi M; Melfa L; Cristinelli L
Cardiovasc Ther; 2010 Dec; 28(6):361-8. PubMed ID: 20553296
[TBL] [Abstract][Full Text] [Related]
11. Managing dyslipidemia in chronic kidney disease.
Harper CR; Jacobson TA
J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
[TBL] [Abstract][Full Text] [Related]
12. Dyslipidemia, statins, and CKD patients' outcomes - review of the evidence in the post-sharp era.
Heymann EP; Kassimatis TI; Goldsmith DJ
J Nephrol; 2012; 25(4):460-72. PubMed ID: 22641572
[TBL] [Abstract][Full Text] [Related]
13. [Chronic kidney disease and atherosclerosis].
Koike M; Nitta K
Nihon Rinsho; 2011 Jan; 69(1):144-50. PubMed ID: 21226275
[TBL] [Abstract][Full Text] [Related]
14. [Anemia as a risk factor for CKD and CVD].
Tsuruya K; Hirakata H
Nihon Rinsho; 2008 Sep; 66(9):1786-93. PubMed ID: 18788410
[TBL] [Abstract][Full Text] [Related]
15. [Statins and kidney disease].
Bigazzi R; Grimaldi D; Bianchi S
G Ital Nefrol; 2012; 29(2):160-73. PubMed ID: 22538946
[TBL] [Abstract][Full Text] [Related]
16. Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy.
Athyros VG; Tziomalos K; Karagiannis A
Expert Rev Cardiovasc Ther; 2015; 13(9):1059-66. PubMed ID: 26206619
[TBL] [Abstract][Full Text] [Related]
17. Lipid management in chronic kidney disease, hemodialysis, and transplantation.
Montague T; Murphy B
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):223-34. PubMed ID: 19217521
[TBL] [Abstract][Full Text] [Related]
18. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
Chapman MJ; Redfern JS; McGovern ME; Giral P
Pharmacol Ther; 2010 Jun; 126(3):314-45. PubMed ID: 20153365
[TBL] [Abstract][Full Text] [Related]
19. HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
Romayne Kurukulasuriya L; Athappan G; Saab G; Whaley Connell A; Sowers JR
Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):49-59. PubMed ID: 19124395
[TBL] [Abstract][Full Text] [Related]
20. [Dyslipidemia and the risk of kidney disease].
Ligabue G; Cavazzini F; Albertazzi A
G Ital Nefrol; 2007; 24 Suppl 38():8-12. PubMed ID: 17922441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
